These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8817830)

  • 41. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
    Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Development of Whole Sporozoite Vaccines for
    Itsara LS; Zhou Y; Do J; Grieser AM; Vaughan AM; Ghosh AK
    Front Immunol; 2018; 9():2748. PubMed ID: 30619241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of human circumsporozoite antibodies in Plasmodium-infected Anopheles (Diptera: Culicidae).
    Beier JC; Oster CN; Koros JK; Onyango FK; Githeko AK; Rowton E; Koech DK; Roberts CR
    J Med Entomol; 1989 Nov; 26(6):547-53. PubMed ID: 2685310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults.
    Jongo SA; Urbano V; Church LWP; Olotu A; Manock SR; Schindler T; Mtoro A; Kc N; Hamad A; Nyakarungu E; Mpina M; Deal A; Bijeri JR; Ondo Mangue ME; Ntutumu Pasialo BE; Nguema GN; Owono SN; Rivas MR; Chemba M; Kassim KR; James ER; Stabler TC; Abebe Y; Saverino E; Sax J; Hosch S; Tumbo AM; Gondwe L; Segura JL; Falla CC; Phiri WP; Hergott DEB; García GA; Schwabe C; Maas CD; Murshedkar T; Billingsley PF; Tanner M; Ayekaba MO; Sim BKL; Daubenberger C; Richie TL; Abdulla S; Hoffman SL
    Am J Trop Med Hyg; 2021 Jan; 104(1):283-293. PubMed ID: 33205741
    [No Abstract]   [Full Text] [Related]  

  • 45. Laboratory methods for the conduct of experimental malaria challenge of volunteers.
    Davis JR
    Vaccine; 1994 Mar; 12(4):321-7. PubMed ID: 8178554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial.
    Bastiaens GJH; van Meer MPA; Scholzen A; Obiero JM; Vatanshenassan M; van Grinsven T; Sim BKL; Billingsley PF; James ER; Gunasekera A; Bijker EM; van Gemert GJ; van de Vegte-Bolmer M; Graumans W; Hermsen CC; de Mast Q; van der Ven AJAM; Hoffman SL; Sauerwein RW
    Am J Trop Med Hyg; 2016 Mar; 94(3):663-673. PubMed ID: 26711509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Humanized DRAGA mice immunized with Plasmodium falciparum sporozoites and chloroquine elicit protective pre-erythrocytic immunity.
    Majji S; Wijayalath W; Shashikumar S; Brumeanu TD; Casares S
    Malar J; 2018 Mar; 17(1):114. PubMed ID: 29540197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
    Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
    Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection.
    Lamsfus Calle C; Fendel R; Singh A; Richie TL; Hoffman SL; Kremsner PG; Mordmüller B
    Front Immunol; 2021; 12():625712. PubMed ID: 33815377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
    Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
    Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men.
    Olotu A; Urbano V; Hamad A; Eka M; Chemba M; Nyakarungu E; Raso J; Eburi E; Mandumbi DO; Hergott D; Maas CD; Ayekaba MO; Milang DN; Rivas MR; Schindler T; Embon OM; Ruben AJ; Saverino E; Abebe Y; Kc N; James ER; Murshedkar T; Manoj A; Chakravarty S; Li M; Adams M; Schwabe C; Segura JL; Daubenberger C; Tanner M; Richie TL; Billingsley PF; Lee Sim BK; Abdulla S; Hoffman SL
    Am J Trop Med Hyg; 2018 Jan; 98(1):308-318. PubMed ID: 29141739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA; Oster CN; Adoyo-Adoyo M; Beier JC; Gachihi GS; Nyakundi PM; Ballou WR; Brandling-Bennett AD; Schwartz IK; Were JB
    Trans R Soc Trop Med Hyg; 1991; 85(3):336-40. PubMed ID: 1949134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.
    Spring M; Murphy J; Nielsen R; Dowler M; Bennett JW; Zarling S; Williams J; de la Vega P; Ware L; Komisar J; Polhemus M; Richie TL; Epstein J; Tamminga C; Chuang I; Richie N; O'Neil M; Heppner DG; Healer J; O'Neill M; Smithers H; Finney OC; Mikolajczak SA; Wang R; Cowman A; Ockenhouse C; Krzych U; Kappe SH
    Vaccine; 2013 Oct; 31(43):4975-83. PubMed ID: 24029408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
    Genton B; Al-Yaman F; Betuela I; Anders RF; Saul A; Baea K; Mellombo M; Taraika J; Brown GV; Pye D; Irving DO; Felger I; Beck HP; Smith TA; Alpers MP
    Vaccine; 2003 Dec; 22(1):30-41. PubMed ID: 14604568
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.
    Steinhardt LC; Richie TL; Yego R; Akach D; Hamel MJ; Gutman JR; Wiegand RE; Nzuu EL; Dungani A; Kc N; Murshedkar T; Church LWP; Sim BKL; Billingsley PF; James ER; Abebe Y; Kariuki S; Samuels AM; Otieno K; Sang T; Kachur SP; Styers D; Schlessman K; Abarbanell G; Hoffman SL; Seder RA; Oneko M
    Clin Infect Dis; 2020 Aug; 71(4):1063-1071. PubMed ID: 31555824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge.
    Talley AK; Healy SA; Finney OC; Murphy SC; Kublin J; Salas CJ; Lundebjerg S; Gilbert P; Van Voorhis WC; Whisler J; Wang R; Ockenhouse CF; Heppner DG; Kappe SH; Duffy PE
    PLoS One; 2014; 9(11):e109654. PubMed ID: 25405724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.